कृपया अन्य खोज का प्रयास करें
Ryvu Therapeutics S.A., a clinical-stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company’s products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Piotr Romanowski | 54 | 2011 | Independent Chairman of the Supervisory Board |
Tadeusz Wesolowski | - | - | Non-Independent Vice Chairman of Supervisory Board |
Rafal Piotr Chwast | - | - | Independent Member of the Supervisory Board |
Axel Gaston Glasmacher | 64 | 2019 | Non-Independent Member of the Supervisory Board |
Peter G. Smith | - | 2023 | Member of Supervisory Board |
Scott Z. Fields | 70 | 2023 | Member of Supervisory Board |
Thomas Turalski | - | 2019 | Non-Independent Member of the Supervisory Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है